Article

Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism

Philipps University of Marburg, Marburg, Hesse, Germany
Fertility and Sterility (Impact Factor: 4.3). 02/2002; 77(2):270-3. DOI: 10.1016/S0015-0282(01)02973-9
Source: PubMed

ABSTRACT To assess the efficacy and safety of recombinant human follicle-stimulating hormone (rhFSH; follitropin alpha) in increasing sperm concentration in 26 men with severe isolated hypogonadotropic hypogonadism (IHH).
Clinical and endocrine studies using an open design.
Six university clinical sites in three European countries.
Azoospermatic patients aged 16 to 48 years with IHH.
Patients received hCG for up to 6 months before 18 months of treatment with rhFSH. Sperm count, motility, and morphology were assessed every 3 months.
Achievement of a sperm concentration of 1.5 x 10(6)/mL.
Spermatogenesis was achieved in 15 of 19 patients who could be evaluated, 12 achieving a sperm concentration of > or =1.5 x 10(6)/mL.
With hCG, rhFSH is effective in initiating spermatogenesis in patients with IHH, and is well tolerated.

0 Bookmarks
 · 
105 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A meta-analysis was performed to systematically analyse the results of gonadotropin and GnRH therapy in inducing spermatogenesis in subjects with hypogonadotropic hypogonadism (HHG) and azoospermia. An extensive Medline and Embase search was performed including the following words: ‘gonadotropins’ or ‘GnRH’, ‘infertility’, ‘hypogonadotropic’, ‘hypogonadism’ and limited to studies in male humans. Overall, 44 and 16 studies were retrieved for gonadotropin and GnRH therapy, respectively. Of those, 43 and 16 considered the appearance of at least one spermatozoa in semen, whereas 26 and 10 considered sperm concentration upon gonadotropin and GnRH, respectively. The combination of the study results showed an overall success rate of 75% (69–81) and 75% (60–85) in achieving spermatogenesis, with a mean sperm concentration obtained of 5.92 (4.72–7.13) and 4.27 (1.80–6.74) million/mL for gonadotropin and GnRH therapy, respectively. The results upon gonadotropin were significantly worse in studies involving only subjects with a pre-pubertal onset HHG, as compared with studies involving a mixed population of pre- and post-pubertal onset [68% (58–77) vs. 84% (76–89), p = 0.011 and 3.37 (2.25–4.49) vs. 12.94 (8.00–17.88) million/mL, p < 0.0001; for dichotomous and continuous data, respectively]. A similar effect was observed also upon GnRH. No difference in terms of successful achievement of spermatogenesis and sperm concentration was found for different FSH preparations. Previous use of testosterone replacement therapy (TRT) did not affect the results obtained with gonadotropins. Finally, a higher success rate was found for subjects with lower levels of gonadotropins at the baseline and for those using both human chorionic gonadotropin and FSH. Gonadotropin therapy, even with urinary derivatives, is a suitable option in inducing/restoring fertility in azoospermic HHG subjects. Gonadotropins appear to be more efficacious in subjects with a pure secondary nature (low gonadotropins) and a post-pubertal onset of the disorder, whereas previous TRT does not affect outcome.
    Andrology 09/2014; 2(6). DOI:10.1111/andr.262 · 3.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infertility affects 6.1 million U.S. couples-representing 10% of reproductive-age adults and 15% of all couples trying to conceive. Half of the time, infertility is the result of an abnormal semen analysis or other male factors, with 40%-50% of these infertile men diagnosed with idiopathic or nonclassifiable infertility. While the role of hormone therapy for men with an identified abnormality is well defined, the literature remains inconclusive and controversial regarding hormone manipulation using empirical (off-label) medical therapies for men with idiopathic infertility. This manuscript reviews the commonly used off-label medications used to treat idiopathic male factor infertility: clomiphene citrate, letrozole/anastrozole, exogenous androgens, and pentoxifylline. Copyright © 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
    Fertility and Sterility 02/2015; DOI:10.1016/j.fertnstert.2014.12.122 · 4.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Congenital hypogonadotrophic hypogonadism (CHH) is a rare form of infertility caused by deficient secretion or action of gonadotrophin-releasing hormone. There is no consensus regarding the optimal approach to fertility treatment in CHH men. In most cases, appropriate hormonal treatment with human chorionic gonadotrophin with or without follicle stimulating hormone will induce testicular development, spermatogenesis and fertility. Recent studies have examined sequential treatment with FSH pre-treatment to optimize fertility outcomes in severely affected CHH patients. This paper reviews historical and recent literature to summarize the current evidence on therapeutic approaches for CHH men seeking fertility. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Best Practice & Research: Clinical Endocrinology & Metabolism 10/2014; 29(1). DOI:10.1016/j.beem.2014.10.005 · 4.91 Impact Factor